Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 8:47 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2473–2496 of 13,628 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Dermatoses Clear all

Conditions: Breast Cancer
Interventions: AEZS-108, SCCC, Dexamethasone; Drug
Lead sponsor: AEterna Zentaris; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Breast Cancer
Interventions: lapatinib ditosylate, paclitaxel albumin-stabilized nanoparticle formulation; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 5
States / cities: Chicago, Illinois • Joliet, Illinois • Olympia Fields, Illinois + 1 more

Conditions: Anxiety, Presurgical Anxiety, Breast Cancer
Interventions: Massage therapy, Standard of care; Procedure
Lead sponsor: Vassar Brothers Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 299 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Poughkeepsie, New York

Conditions: Breast Cancer
Interventions: docetaxel, imatinib mesylate; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2011
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Breast Cancer, Autoimmune Disease, Prostate Cancer, Ovarian Cancer, Endometrial Cancer
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 10,805 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Atopic Dermatitis
Interventions: Upadacitinib 15mg Dose, Dupilumab 300mg Dose, Upadacitinib 30mg Dose; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 63 Years
Enrollment: 184 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 84
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Fayetteville, Arkansas + 70 more

Conditions: Cancer, Non-small-cell Lung Cancer, Breast Cancer
Interventions: XL647, XL147; Drug
Lead sponsor: Exelixis; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 2
States / cities: New York, New York • San Antonio, Texas

Conditions: Breast Cancer, Musculoskeletal Complications, Pain
Interventions: duloxetine hydrochloride, placebo; Drug · Other
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: Up to 120 Years · Female only
Enrollment: 299 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 714
States / cities: Anchorage, Alaska • Fairbanks, Alaska • Jonesboro, Arkansas + 475 more

Conditions: Melanoma (Skin)
Interventions: dendritic cell-MART-1 peptide vaccine, gp100 antigen, therapeutic tumor infiltrating lymphocytes, tyrosinase peptide; Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2002
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Tibial Delayed Healing
Interventions: INFUSE/MASTERGRAFT, Autograft bone; Device · Procedure
Lead sponsor: Medtronic Spinal and Biologics; Industry
Eligibility: 21 Years and older
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 16
States / cities: Denver, Colorado • Fort Lauderdale, Florida • Jacksonville, Florida + 13 more

Conditions: Breast Cancer
Interventions: watch DVD and small group discussion, watch DVD; Behavioral
Lead sponsor: Georgetown University; Other
Eligibility: 42 Years and older · Female only
Enrollment: 954 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 3
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Philadelphia, Pennsylvania

Conditions: Acne Vulgaris
Interventions: Formulation A, Formulation B; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 13 Years to 35 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Breast Cancer
Interventions: Blood Draw; Diagnostic Test
Lead sponsor: University of Virginia; Other
Eligibility: 45 Years and older · Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Vascular Ehlers-Danlos Syndrome
Interventions: Heartmath Intervention, Control Group; Other
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 12 Years to 45 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Estrogen Receptor-positive (ER+)/Human Epidermal Growth Factor Receptor (HER2)-Negative Locally Advanced or Metastatic Breast Cancer
Interventions: Venetoclax, Fulvestrant; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 21
States / cities: Phoenix, Arizona • Springdale, Arkansas • La Jolla, California + 18 more

Conditions: Breast Cancer, Hot Flashes
Interventions: gabapentin, antidepressant; Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older · Female only
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 162
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Augusta, Georgia + 101 more

Conditions: Breast Cancer
Interventions: Not listed
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 65 Years and older · Female only
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2026
U.S. locations: 2
States / cities: Duarte, California • South Pasadena, California

Conditions: Psoriasis, Atopic Dermatitis
Interventions: XmAb27564, Placebo; Biological
Lead sponsor: Xencor, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 6
States / cities: Sherman Oaks, California • Thousand Oaks, California • Coral Gables, Florida + 3 more

Conditions: Systemic Sclerosis (SSc)
Interventions: Apollo Neuro Device, Sham device; Device
Lead sponsor: Robyn T. Domsic, MD, MPH; Other
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 4
States / cities: New Orleans, Louisiana • Ann Arbor, Michigan • Pittsburgh, Pennsylvania + 1 more

Conditions: Hair Loss, Skin Laxity, Cosmetic Acne, Nails; Soft, Skin Aging
Interventions: Vegetarian Collagen, Keratin, Ceramides, Astaxanthin; Dietary Supplement
Lead sponsor: ProofPilot; Industry
Eligibility: 26 Years to 100 Years
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Breast Cancer, Solid Tumors
Interventions: PF-07220060 + PF-07104091 combination dose escalation, PF-07104091 + PF-07220060 + fulvestrant dose expansion, PF-07104091 + PF-07220060 + letrozole dose expansion; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 235 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 12
States / cities: Los Angeles, California • Santa Monica, California • Boston, Massachusetts + 5 more

Conditions: Kidney Cancer, Melanoma (Skin)
Interventions: recombinant interferon alfa, recombinant interleukin-12; Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2008
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Cutaneous Squamous Cell Carcinoma in Situ, Facial Cutaneous Squamous Cell Carcinoma in Situ, Cutaneous Squamous Cell Carcinoma, Upper Extremities/Trunk Cutaneous Squamous Cell Carcinoma
Interventions: Aminolevulinic Acid 20% Topical Solution with Blue Light (dose 20 J/cm2), Aminolevulinic Acid 20% Topical Solution with Blue Light (dose 10 J/cm2); Combination Product
Lead sponsor: The Center for Clinical and Cosmetic Research; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Aventura, Florida

Conditions: Mastectomy, Breast Cancer
Interventions: Liposomal bupivacaine, Standard bupivacaine, Placebo; Drug · Other
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Search by objective public record fields.

Phase 2 Trial of AEZS-108 in Chemotherapy Refractory in Triple Negative Breast Cancer

Abraxane and Lapatinib in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer

Preoperative Massage in Breast Surgery Patients

Docetaxel and Imatinib Mesylate in Treating Patients With Locally Advanced or Metastatic Breast Cancer

Continuation of Follow-up of DES-Exposed Cohorts

A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab

Safety Study of XL647 and XL147 Administered in Combination Daily in Adults With Solid Tumors

S1202: Duloxetine Hydrochloride for Muscle/Joint Pain in Early-Stage Breast Cancer Receiving Hormone Therapy

Vaccine Therapy in Treating Patients With Stage IV Melanoma

Tibial Delayed Healing Pivotal Clinical Trial

Breast Health in Chinese American Women

Comparison of Two Salicylic Acid Formulations

Immune Effects in Patients Treated With Whole Breast Irradiation

Heart Coherence Training on Vascular Ehlers-Danlos Syndrome Patients

A Phase II Study Comparing The Efficacy Of Venetoclax + Fulvestrant Vs. Fulvestrant In Women With Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer Who Experienced Disease Recurrence Or Progression During Or After CDK4/6 Inhibitor Therapy

Gabapentin With or Without Antidepressants in Treating Hot Flashes in Women Who Have Had Breast Cancer or Have Concerns About Taking Hormone Therapy

Brain Functional MRI in Older Women With Breast Cancer (Brain fMRI-BC)

Multiple Ascending-Dose Study of XmAb®27564 in Patients With Psoriasis or Atopic Dermatitis

The Apollo Device in Systemic Sclerosis for the Management of fatiguE, Raynaud Phenomenon and qualiTy of Life

Nourishing Hair, Skin & Nails Supplement Study (Derm Aid)

A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors

Interleukin-12 and Interferon Alfa in Treating Patients With Metastatic Kidney Cancer or Malignant Melanoma

Evaluating Photodynamic Therapy Used to Treat Cutaneous Squamous Cell Carcinoma in Situ (isSCC) on the Face, Upper Extremities & Trunk.

Post-Mastectomy Analgesia Using Exparel (Liposomal) Versus Standard Bupivacaine or Placebo